Vera Therapeutics to Participate at September Investor Conferences
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotech company, announced its participation in two investor conferences in September 2024. The company, which focuses on developing treatments for serious immunological diseases, will attend:
1. Wells Fargo Healthcare Conference on September 5 in Boston, MA, participating in one-on-one meetings.
2. Cantor Global Healthcare Conference on September 18 in New York, NY, featuring a fireside chat at 9:10am EDT and one-on-one meetings.
A webcast of the Cantor conference presentation will be available, with a 90-day replay accessible on Vera Therapeutics' website in the 'Investor Calendar' section.
Positive
- None.
Negative
- None.
News Market Reaction – VERA
In the trading session that priced this news, VERA gained 0.22%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at investor conferences being held in September.
Investor Conference Details:
- Wells Fargo Healthcare Conference
Format: 1x1s
Date: Thursday, September 5, 2024
Location: Boston, MA - Cantor Global Healthcare Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/cantor22/vera/2084634
Date: Wednesday, September 18, 2024
Time: 9:10am EDT
Location: New York, NY
A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Advisors
MHawtin@lifescicomms.com
